Patient Characteristics, Treatment, and the Distribution Between Age Subgroups Abbreviations: BCT = breast-conserving therapy; ER = estrogen receptor; MRM = modified radical mastectomy; NS = not significant; PgR = progesterone receptor small patient subgroup. Menopausal status at diagnosis is a decisive factor in the choice of (neo)adjuvant treatment and, thus, of potentially confounding nature when not accounted for. Moreover, menopausal status must be taken into account in the course of identifying more precise biological factors for the comparatively poor outcome instead of the current surrogate marker in use: young age. In this retrospective analysis, the relationship of age, prognostic factors, and treatment on recurrence-free and overall survival was investigated in a well-defined, homogeneous population of premenopausal patients with breast cancer. Recent literature that has contributed to our knowledge of breast cancer in women ≤ 35 years of age is also discussed.
Patients and Methods

Patients
All premenopausal patients with operable breast cancer who received primary treatment at the Surgical Department or the Gynecological Department of the University of Vienna between 1966 and 1999 were identified from a computerized database. Data collection included well-known prognostic markers (Table 1) , surgical treatment, adjuvant treatment, and time of recurrence and death. Patients whose records were not available or incomplete were eliminated from the analysis. Women with a history of previous cancer, bilateral cancer, inflammatory cancer or in situ carcinoma, and distant metastasis at the time of diagnosis were also excluded.
In accordance with published data, the entire study population was divided into two groups as a function of age: ≤ 35 years and > 35 years at the time of surgical treatment. Eight hundred eighty-five patients were eligible for this study: 81 (9.2%) in the younger age group and 804 (90.8%) in the older age group. This age distribution is representative of the general population treated for breast cancer in Western Europe. The two age groups were grouped according to the time of surgery (1966-1979, 1980-1989, and 1990-1999) . The distribution of patients in both groups was proportionally equal during these time spans.
Study Parameters
In order to assess the prognostic role of age, the following parameters were studied: tumor size (invasive component), tumor type, tumor grading, pathologic lymph node status, and hormone receptor status.
Tumor size was defined from the pathologic size immediately after surgery. Histologic grade was determined according to the Scarff-Bloom-Richardson system. 24 Estrogen receptor (ER) and progesterone receptor (PgR) contents were assayed by the dextran-coated charcoal method and Scatchard analysis as described previously. 25 A level of at least 10 fmol/mg, cytosol protein was considered as receptor positive. Applying immunocytochemical analysis, 10% positive cells indicate a positive receptor. 26 Regular menstrual cycles or cessation of menses no more than 1 year before the time of surgery defined premenopausal status in this study. Peripheral hormone status was assessed in cases of doubt.
Treatment Technique
Surgical treatment consisted of conservative breast-conserving therapy (BCT) or modified radical mastectomy (MRM). Both procedures included axillary dissection of at least levels I and II. No routine chemotherapy was administered until 1970. As of 1975, perioral cyclophosphamide/methotrexate/ 5-fluorouracil (CMF) according to the original Bonadonna scheme was in use until 1985, when intravenous CMF or 5-fluorouracil/epirubicin/cyclophosphamide (FEC) treatment became available and was applied according to published protocols of the Austrian Breast and Colorectal Cancer Study Group (ABCSG). [27] [28] [29] [30] [31] Furthermore, endocrine treatment (eg, tamoxifen) was administered when it became available in the presence of hormone receptor positivity. In the majority of BCT cases, radiotherapy was administered at a total dose of 50 Gy, including a 10 Gy boost to the tumor bed in most cases.
Follow-up
During the first 3 years after surgery, all patients were evaluated every 3 months. After this first period, patients were followed in 6-month intervals until the fifth year postsurgery. Further follow-up is conducted annually or more often if adverse prognostic factors persist. Evaluation consisted of clinical examination and laboratory analysis at every consultation, and mammography yearly, or more frequently, if indicated. Chest x-rays and liver ultrasounds were carried out in 6-month intervals. All patients had bone scans after surgery. This examination was repeated during follow- 
Covariates for Univariate and Multivariate Analyses
Statistical Methods
Data were stored in an IBM 3090 computer at the Vienna University Medical School using SAS ® software (SAS ® Institute, Cary, NC) for data processing, management, and analysis. Statistical analyses of survival were based on appropriate programs of BMDP (BMDP Statistical Software Inc., Los Angeles, CA).
Univariate description of continuous factors was performed by estimates of mean and standard deviations and upper and lower quartiles (χ 0.25 , χ 0.75 ). The median and quartiles of follow-up time were derived from a KaplanMeier analysis with the meaning of the survival status indicator reversed.
Spearman rank correlation coefficients and corresponding tests were used to analyze monotonic associations between the prognostic factors considered. All prognostic factors considered in the analyses were dichotomized using suitable cutoffs to simplify the presentation of results and to more easily judge goodness of fit in the modeling process. Survival was expressed as time from the date of primary treatment of breast cancer to the occurrence of an event and was analyzed in 3 ways: in terms of overall survival, relapsefree survival, and locoregional relapse-free survival. Relapsefree survival was defined as the interval between the date of operation and the first recurrence (local or distant) of breast cancer. Survival curves for all analyses were calculated by the Kaplan-Meier method. Differences between curves were assessed with Wilcoxon (Breslow) and Mantel's log rank test for censored survival data. All data for multi-and univariate analyses were censored at 120 months of follow-up time.
Multivariate analysis by Cox's proportional hazards model served to quantify and confirm the role of prognostic factors after simultaneous adjustment of all other factors considered. In a step-wise fashion, all prognostic factors were eliminated from the model for which no independent effect on survival could be confirmed (P > 0.15). Covariates for uni-and multivariate analyses are listed in Table 2 .
In all Cox analyses reported, 2-sided P values are accompanied by estimates of the relative risk of death (RR) including a 95% confidence interval (CI), comparing the unfavorable to the more favorable level of each factor.
Results
The 
Patient Characteristics and Patient Treatment Factors
Patient characteristics in both age groups were very sim- 
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*All tumor types and overall survival: P < 0.0003 † All local therapies (LT) and overall survival: P < 0.08; LT and relapse-free survival: P < 0.0007; LT and locoregional relapse-free survival: P < 0.01 Abbreviations: CI = confidence interval; NS = not significant; RR = relative risk ilar in respect to all recorded data as listed in Table 1 . Although a trend toward a higher number of G3 tumors, ERnegative tumors, or PgR-negative tumors was observed, the prevalence of adverse pathologic prognostic features such as tumor size and lymph node metastasis showed an even distribution without statistical significance. The breast conservation rate was close to 50% in both groups. Radiotherapy was administered to 41.6% of all women, with an even distribution in both groups. Young women were more likely to receive chemotherapy (P < 0.044) and were less likely to receive adjuvant hormonal therapy (P < 0.048).
Univariate Relationship of Age and Overall Survival
Overall survival in both age groups was 82% at 5 years and 67% at 10 years of follow-up. Separate analysis of age groups showed decreased overall survival for young patients (74.3% at 5 years, 65.7% at 10 years) versus patients > 35 years (83.1% at 5 years, 67.6% at 10 years; Figure 1 ). This difference between survival curves was significant in a generalized Wilcoxon log rank test (P < 0.01) but showed no statistical significance in Mantel's log rank test (P < 0.07).
Univariate Relationship of Age and Recurrence-Free Survival
The survival disadvantage for patients ≤ 35 years of age was even more marked comparing recurrence-free survival data (Figure 2 ). Recurrence-free survival for patients ≤ 35 of age years was 58.1% at 5 years and 58.0% at 10 years compared with 75.2% at 5 years and 66.4% at 10 years for patients > 35 years of age. This difference was highly significant in both log rank tests (Mantel's: P < 0.007; Wilcoxon: P < 0.002).
Multivariate Analyses
Age, nodal status, tumor size, grading, and hormone receptors were taken into account in the Cox model (Table 2) . Locoregional treatment was grouped as BCT with or without radiotherapy versus mastectomy. Adjuvant therapy consisting of either chemotherapy or hormonal therapy was also assessed to determine the prognostic value. Age proved to be an independent prognostic factor for survival. Women in the young age group showed a 2.2-times-higher RR of death (P < 0.0039) and a 2.5-times-higher risk of recurrence (P < 0.0001; Table 4 ). A significant increase in local recurrence in the young age group was not found.
The most powerful independent risk factor proved to be nodal involvement with a risk ratio of death increased by a factor of 4.7 (P < 0.0001), a risk of recurrence increased by 2.9 (P < 0.0001), and a 3.7-times-higher risk of locoregional recurrence (Table 4) . Positive PgR decreased the risk of death by a factor of 0.6 (P < 0.03).
Radiotherapy after BCT decreased the risk of recurrence by a factor of 0.6 (95% CI: 0.4-0.9) in this premenopausal cohort. In terms of local recurrence, patients receiving BCT without adjuvant radiotherapy had 2.2 times the risk (95% CI: 1.0-5.2) of patients treated by MRM, while patients in the BCT subset who had undergone radiotherapy were at half the relative risk (RR = 0.5; 95% CI: 0.2-1.3). Hormone therapy or chemotherapy did not influence survival in multivariate analysis. No interaction was identified between age and adjuvant therapies received.
Discussion
This retrospective analysis of 885 premenopausal patients treated at two institutions in a single hospital scruti-
Young Age and Breast Cancer
Overall Survival and Age nized data on the prevalence of important prognostic features in breast cancer. In order to investigate a sufficient number of young patients, this analysis is based on a period beginning in 1966. Although this might be considered a limitation to the analysis, the focus of this study was to determine whether differences exist between younger and older patients within a strictly defined premenopausal population. Data documenting the differential distribution of prognostic factors and survival irrespective of menopausal status may be lacking in accuracy in this respect and reflect differences between pre-and postmenopausal breast cancer. It is in view of these hypothesized differences that differential treatment of younger women should to be discussed. An important finding in this context was the even distribution of adverse prognostic features. Comparable studies investigating premenopausal patients have to some extent identified significant associations of at least some characteristics (eg, low differentiation, negative hormone receptors, or nodal involvement) in the young age group. 14, 16, 23 Nevertheless, these differences are certainly much more consistent when the young age group within the premenopausal population is compared to an older group, irrespective of menopausal status, or to postmenopausal women. 8, 9, 11, 15, 16 This well-reviewed phenomenon 32, 33 reflects biological differences in breast cancer of pre-and postmenopausal women and underlines our determination to review our own data in an exclusively premenopausal population.
Against the background of evenly distributed histopathological data, treatment modalities, and the use of multivariate statistical analysis, age as an independent prognostic parameter in overall and disease-free survival stands out as the most important finding of this report. Nevertheless, some important variables were unavailable for this analysis. Mutations in p53, overexpression of c-erB-2, and markers of tumor proliferation are all associated with young age. 9, 13, 34, 35 In some instances, the inclusion of these adverse prognostic factors in multivariate analyses is reported to replace the age variable as an independent prognostic factor. 32 Age was not correlated to locoregional relapse-free survival in this study. There are two early reports from Institut Curie identifying young age as a very significant risk factor in local recurrence, 36, 37 and among more recent literature, this is a fairly consistent finding. 38, 39 Within the young age group comprising 81 patients (> 35 years), there was a total of 9 local recurrences within total follow-up time. Thus, statistical analysis within our population can not reliably add information to this issue. Moreover, one may speculate that the difference between younger and older patients in incidence of local recurrence may indeed be quite small within a premenopausal population.
The question of local therapy and survival in premenopausal women has been addressed by setting the RR of patients treated with MRM at 1.0 and comparing these patients with BCT and radiation therapy-treated women. Radiation therapy after BCT showed a strong decrease in the RR of recurrence. Although multifocality and p53 expression, two important independent risk factors for local recurMultivariate Analyses of Overall Survival, Relapse-Free Survival, and Locoregional Relapse-Free Survival Table 4 Age 
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rence in young patients, 38 were not included in our Cox model, the importance of radiotherapy could be affirmed. This is consistent with recent review data on radiotherapy for early breast cancer 40, 41 and underlines the importance of radiotherapy in premenopausal patients. Worse prognosis associated with young age raises the issue of chemotherapy for this patient group. Kroman and colleagues 42 addressed this question in a large retrospective cohort study comprising 10,356 women < 50 years of age. In this study the negative prognostic effect of young age was almost exclusively found in a subgroup of very young women with little adverse prognosticators that had not received chemotherapy. Thus, on the basis of age alone, the authors state the benefit of adjuvant cytotoxic therapy. In a second recent study 43 of young pre-and perimenopausal women treated with various regimens of CMF, the authors identified a decreased disease-free survival in young estrogen receptor-positive women. The interpretation of this data leads to speculation on the need for additional hormonal adjuvant treatment in this patient group, particularly when chemotherapy does not result in amenorrhea. 44 According to the St Gallen guidelines, no woman under the age of 35 years at diagnosis should be considered at low risk. Even though the development of treatment protocols is ongoing, current data imply that young patients derive a benefit from radiotherapy, hormonale therapy, and chemotherapy, and, in some cases, profit more than older premenopausal patients at the same risk profile. The precise reasons why the very young patients in our study differ as to treatment responses have not been clearly established. 45 
Conclusion
In our analysis, young age is identified as an independent prognostic factor, thus making clear that future research must direct its focus on unveiling the surrogate young age. Already, a great number of prognostic and predictive factors are under investigation and, hopefully, the future study of differential gene expression patterns will not only substitute for this age surrogate, but will also facilitate treatment that may elevate the poor level of prognosis with which it is associated.
